Domainex Ltd and Ark Therapeutics have extended their drug discovery agreement. Domainex will continue providing hit-finding and lead optimization services for Ark's therapeutic targets. The companies have worked together successfully for years, combining Domainex's drug design expertise with Ark's disease expertise. Dr. Trevor Perrior of Domainex commented that their collaboration has already achieved breakthroughs against challenging goals, and they look forward to further developing programs to deliver new disease treatments.